Darifenacin Hydrobromide

Specifications

133099-07-7CAS Number

603-705-7EC Number

2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromideIUPAC Name

C28H31BrN2O2Chemical Formula

507.5 g/molMolecular Weight

Darifenacin hydrobromide; 133099-07-7; darifenacin HBr; UK 88525-04 hydrobromide; DTXSID9046780; CR02EYQ8GV; UK-88525-04 (HYDROBROMIDE); Uk-88525-04 (hbr); DTXCID7026780; CHEBI:31455; (S)-2-{1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide hydrobromide; (S)-2-(1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)-3-PYRROLIDNYL)-2,2-DIPHENYLACETAMIDE HYDROBROMIDE; (S)-2-{1-[2-(2,3-Dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidnyl}-2,2-diphenylacetamide hydrobromide; Darifenacin 15 mg; Darifenacin 7.5 mg; RefChem:57151; Enablex; Emselex; MFCD08141803; Darifenacin hydrobromide [USAN]; Darifenacin (hydrobromide); (S)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide hydrobromide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide hydrobromide; 3-PYRROLIDINEACETAMIDE, 1-[2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL]-ALPHA,ALPHA-DIPHENYL-, HYDROBROMIDE (1:1), (3S)-; Darilong; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide; CAS-133099-07-7; NCGC00168775-01; UNII-CR02EYQ8GV; C28H31BrN2O2; Emselex;; (S)-2-[1-[2-(2,3-Dihydrobenzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide hydrobromide; Enablex (TN); Darifenacinhydrobromide; 133099-07-7 (HBr); SCHEMBL453486; orb1226529; orb1308291; CHEMBL1200935; SCHEMBL29519864; HY-A0012R; GLXC-05124; HY-A0012; Tox21_112636; Darifenacin hydrobromide (JAN/USAN); DARIFENACIN HYDROBROMIDE [MI]; EBC-11257; s3144; DARIFENACIN HYDROBROMIDE [JAN]; AKOS015969311; Darifenacin (hydrobromide) (Standard); Tox21_112636_1; AC-1894; CCG-220969; CS-0380; FD10806; DARIFENACIN HYDROBROMIDE [MART.]; DARIFENACIN HYDROBROMIDE [USP-RS]; DARIFENACIN HYDROBROMIDE [WHO-DD]; NCGC00168775-04; NCGC00263922-02; 3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (3S)-; 3-Pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, monohydrobromide, (S)-; AS-35087; SY103034; DARIFENACIN HYDROBROMIDE [EMA EPAR]; Darifenacin hydrobromide, >=98% (HPLC); SW219426-1; DARIFENACIN HYDROBROMIDE [ORANGE BOOK]; UK-88525-04; D01699; EN300-123031; F794024; Q27114313; Z1546616192; (S)-2-[1-[2-(2,3-Dihydrobenzfuran-5-yl)ethyl]-3-pyrrolidinyl]-2,2-diphenylacetamide HBr; Darifenacin hydrobromide, United States Pharmacopeia (USP) Reference Standard; (1-[2-(2,3-Dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide hydrobromide; (S)-2-(1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)-3-PYRROLIDNYL)-2,2-DIPHENYLACETAMIDE HBR; 2-[(3S)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenyl-acetamide;hydrobromide; 2-{(3S)-1-[2-(2,3-Dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide--hydrogen bromide (1/1); 3-PYRROLIDINEACETAMIDE, 1-(2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL)-.ALPHA.,.ALPHA.-DIPHENYL-, MONOHBR, (3S)-; 3-PYRROLIDINEACETAMIDE, 1-(2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL)-.ALPHA.,.ALPHA.-DIPHENYL-, MONOHYDROBROMIDE, (3S)-; 3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-|A,|A-diphenyl-, hydrobromide (1:1), (3S)-Synonyms